drugset
drugset / Trial / NCT04447404

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

NCT04447404 ↗

Phase 2 Terminated 2 enrolled Durect
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2

Timeline

Start
2020-09-21
Primary completion
2021-03-04
Completion
2021-03-04

Outcome

Outcome not reported

Stopped (Enrollment): “low enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Larsucosterol Small molecule — Intravenous

Indications

COVID-19